Several purported shareholder class action lawsuits have been filed against Able Laboratories, Inc. and certain of its present and former executive officers charging the defendants with violations of the Securities Exchange Actof 1934. More specifically, the Complaint alleges that the Company failed to disclose and misrepresented the following material adverse facts which were known to defendants or recklessly disregarded by them: (1) that the Company's laboratory testing practices significantly deviated from standard operating procedures employed in the industry; (2) that as a consequence of the foregoing, the Company suspended shipment of all of its products and had to withdraw seven of its approved Abbreviated New Drug Applications filed with the FDA; and (3) that this disruption of business would have a material adverse effect on the Company's business and results of operations.

The complaint further alleges that on or around May 19, 2005, Able announced that it had identified apparent departures from standard operating procedures with respect to certain laboratory testing practices. On the same day, Able also announced that defendant, the Company's Chairman and Chief Executive Officer, would be resigning from those positions. The news shocked the market. Shares of Able fell $18.37 per share, or 74.59 percent, on May 19, 2005, to close at $6.25 per share.

If you bought Able Laboratories, Inc. securities between October 31, 2002 and May 18, 2005, inclusive, and would like to obtain information about the lawsuit, then you are invited to call (866) 467-1400 to speak with an attorney.